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Different solid forms of an active pharmaceutical ingredient can have distinct chemical and physical 
characteristics. In this work, we studied the solubility and dissolution properties of the described 
tibolone polymorphic forms (I and II). Both forms were successively recrystallized and characterized 
by powder X-ray diffraction and attenuated total reflection infrared spectroscopy. Equilibrium solubility 
and dissolution profiles were performed for both forms. Solubility studies demonstrated that form II is 
statistically more soluble in water, 0.01 mol L-1 HCl and pH 4.5 acetate buffer. The solubility of forms 
I and II were explained in terms of crystal packing. Dissolution tests of tablets showed a lower release 
of polymorphic form II than form I from tablets. The results showed an impact of polymorphism on the 
quality of tibolone tablets and suggest that tibolone forms I and II can show distinct interactions with 
pharmaceutical excipients used in tablets. Therefore, only form I is acceptable for the preparation of 
tablet forms. Based on our results, we propose the quality control on tibolone raw materials using X-ray 
diffraction analysis and attenuated total reflection infrared spectroscopy.
Keywords: Tibolone/polymorphs. Powder X-ray diffraction/methods. Infrared spectroscopy/methods. 
Solubility/drug effects. Dissolution/analysis.
INTRODUCTION
It is known that different forms of solids for an 
active pharmaceutical ingredient (API) can show different 
chemical and physical characteristics, which will affect 
the manufacturability, performance, and/or quality of a 
drug product (Karabas, Orkoula, Kontoyannis, 2007). 
Among the physicochemical properties that can influence 
the quality of APIs, solubility and dissolution rate are 
key because they are directly related to bioavailability 
(Delori, Friščić, Jones, 2012). Therefore, the study of 
these properties for different crystalline forms of any drug 
substance is of great importance. 
Tibolone (17-hydroxy-7α-methyl-19-nor-17α-
pregn-5(10)-en-20-yn-3-one), also known as Org 
OD14, 17αMNa or 7 alpha, was patented in 1967 by the 
company OrganonTM (De Jongh, Van Vliet, 1967). It is a 
hormonal substance with a tissue-specific action used in 
the treatment of climacteric symptoms and the prevention 
of osteoporosis in postmenopausal women (Kenemans, 
Speroff, 2005). Tibolone is practically insoluble in water 
and is commercialized as 2.5 mg oral tablets (brand name: 
LivialTM, produced by Akzo OrganonTM). 
To the best of our knowledge, two crystalline 
structures have been described for tibolone to date. 
The first crystal phase, named form I, was determined 
by Declercq, Van Meerssche, Zeelen (1984) in a P21 
monoclinic space group (a = 6.542(2) Å, b = 41.213(9) 
Å, c = 6.678(2) Å, β = 101.64(2)°). The second known 
phase, named form II, was found some years later by 
Schouten, Kanters (1991) (triclinic P1, a = 6.542(2) Å, 
b = 6.677(<1) Å, c = 10.287(2) Å, α = 87.05(1)°, 
β = 80.09(2)°, γ = 79.17(2)°). Form I has two independent 
by symmetry molecules in the asymmetric unit. 
The overlay of them shows that their intramolecular 
geometries differ significantly considering the 
cyclohexanone moiety (Figure 1). This means that 
tibolone shows two different half-chair conformers in 
form I, while form II contains just one molecule and its 
intramolecular geometry matches well with one of the 
two molecules in form I (Figure 1). 
R. Bonfilio, M. C. O. Souza, J. S. Leal, O. M. M. S. Viana, A. C. Doriguetto, M. B. Araújo
Braz. J. Pharm. Sci. 2017;53(4):e00233Page 2 / 12
Form I is the most thermodynamically stable 
crystal form and preferentially used in formulations 
(Sas, Van Doornum, 1991). Form I is obtained by 
crystallizing tibolone in polar solvents such as acetonitrile 
or acetone. Form II can be obtained by crystallization 
in nonpolar solvents as hexane and toluene. However, 
the crystallization of both forms can occur concurrently. 
Therefore, as the degree of supersaturation and temperature 
are not easily controlled on an industrial scale, there is the 
possibility of a mixture of polymorphs in raw materials 
(Boerrigter et al., 2002).
There are descriptions of tibolone polymorphs’ 
characterization by Powder X-ray Diffraction (PXRD), 
Polarized-light Optical Microscopy (POM), Scanning 
Electron Microscopy (SEM), Raman Spectroscopy 
(RS), Infrared Spectroscopy (IR), Differential Scanning 
Calorimetry (DSC) and Thermogravimetry (TG) (Sas, 
Van Doornum, 1991; Boerrigter et al., 2002; Araujo et 
al., 2010a, Araujo et al., 2010b). Nevertheless, to the 
best of our knowledge, there have been no published 
papers studying the influence of tibolone polymorphs on 
the physicochemical quality of tablets, particularly with 
respect to aqueous solubility and dissolution profiles. 
Thus, the aims of this study were to study the solubility 
and the dissolution properties of tibolone forms I and II.
MATERIAL AND METHODS
Material
Tibolone, British Pharmacopoeia Chemical 
Reference Substance (BPCRS), batch number 3053 and 
with a declared content of 99.2%, was purchased from 
British Pharmacopoeia (London, United Kingdom). 
Tibolone raw material was acquired from Shanghai Bio-
Tech Co., Ltd.TM (Shanghai, Shanghai, China). LivialTM 
tablets (Shering-PloughTM, São Paulo, São Paulo, Brazil) 
containing 2.5 mg of tibolone were purchased from the 
local market. Toluene, pyridine, hydrochloric acid, sodium 
hydroxide and potassium dihydrogen phosphate were 
purchased from VetecTM (Rio de Janeiro, Rio de Janeiro, 
Brazil), acetone and glacial acetic acid from ProquímiosTM 
(Rio de Janeiro, Rio de Janeiro, Brazil), citric acid from 
IsofarTM (Duque de Caxias, Rio de Janeiro, Brazil) and 
sodium lauryl sulfate from DinâmicaTM (Diadema, São 
Paulo, Brazil). These reagents were of analytical grade. 
Acetonitrile and methanol were of High Performance 
Liquid Chromatography (HPLC) grade and were obtained 
from VetecTM (Rio de Janeiro, Rio de Janeiro, Brazil). 
Ultrapure grade water was prepared using a Direct-QTM 
water system (MilliporeTM, Bedford, USA) and meets U.S. 
Pharmacopoeia requirements.
Polymorphs’ recrystallization
Recrystallization of tibolone form I was performed 
according to the literature (Sas, Van Doornum, 1991; 
Araujo et al., 2010a), with slight modifications: 2.0 g 
of tibolone raw material were dissolved at 20–25 °C in 
46 mL of acetone, to which 12 microliters of pyridine 
was added. The solution was then filtered, and 12 mL of 
ultrapure water was added to the filtered solution under 
nitrogen and agitation. We observed the formation of a 
suspension. The suspension was cooled in an ice bath and 
stirred at 150 rpm for 1 hour. The crystals were filtered 
off, washed with ultrapure water and dried at 40 °C under 
vacuum in a desiccator containing silica gel as a drying 
agent. Thereafter, the dried crystals were sieved using 
stainless steel mesh and the size fraction between 106 
μm (150 mesh) and 150 μm (100 mesh) was selected for 
further studies.
Recrystallization of tibolone form II was performed 
according to the literature (Sas, Van Doornum, 1991; 
Araujo et al., 2010a), with slight modifications: 5.0 g of 
FIGURE 1 – Perspective view showing the superposition of form I (conformers 1 and 2 in green and blue, respectively) and form 
II (in red) of tibolone. The molecular backbones were generated from the known crystal structures (Declercq, Van Meerssche, 
Zeelen, 1984; Schouten, Kanters, 1991). The hydrogen atoms were hidden for clarity.
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tibolone raw material was dissolved at 40 °C in 215 mL 
of toluene under agitation. This solution was allowed to 
cool to room temperature and was kept in a refrigerator 
at 5–10 °C for 72 hours. The crystals were filtered off and 
dried at room temperature under vacuum in a desiccator 
containing silica gel as a drying agent. The crystals were 
then sieved using stainless steel mesh and the size fraction 
between 106 μm (150 mesh) and 150 μm (100 mesh) was 
selected for further studies.
Polymorphs characterization
Tibolone forms I and II were characterized by 
powder X-ray diffraction (PXRD) and attenuated total 
reflectance/Fourier transform infrared spectroscopy (ATR/
FTIR). 
The PXRD patterns were recorded at room 
temperature on a RigakuTM Ultima IV (type II) X-ray 
diffractometer (Rigaku Co., Ltd., Tokyo, Japan). The 
samples were individually mounted on grooved glass 
slides used as sample holders. Analyses were performed 
using Cu-Kα radiation (λ = 1.5418 Å), at a voltage of 
40 kV and current of 30 mA. Each pattern consisted of 
1251 steps, ranging from 5° to 30° in 2θ, with a step size 
of 0.02° and scan speed of 1° 2θ per minute.
ATR/FTIR spectra were obtained using an 
Affinity-1 Fourier Transform infrared spectrophotometer 
(ShimadzuTM, Tokyo, Japan) coupled to a Pike Miracle™ 
attenuated total reflectance sampling accessory with ZnSe 
waveguides (Pike Technologies™, Madison, Wisconsin, 
USA). Spectra were recorded at room temperature in 
the 3500-500 cm-1 range. After recording a background 
spectrum, the samples were placed on the crystal. In each 
sample, 32 scans were recorded with resolution of 4 cm-1.
Solubility studies of tibolone polymorphs
To determine the solubility of tibolone polymorphs, 
each form was added in excess to 25 mL amber glass flasks 
containing 10 mL of the following solvents: ultrapure 
water, 0.1 M HCl, 0.01 M HCl, pH 3.0 citrate buffer 
(0.18 mol.L-1), pH 4.5 acetate buffer (0.050 mol.L-1), 
pH 5.8 potassium phosphate buffer (0.054 mol.L-1), 
pH 6.8 potassium phosphate buffer (0.072 mol.L-1), and 
pH 7.2 potassium phosphate buffer (0.085 mol.L-1). The 
solutions were prepared in triplicate. Subsequently, the 
flasks were agitated at 150 rpm at room temperature using 
a shaker table SolabTM model SL 180 DT (Piracicaba, São 
Paulo, Brasil). After 48 hour-stirring, the concentration of 
each polymorph in each solvent was determined using a 
validated stability-indicating HPLC method. 
The remaining solid was dried in a desiccator 
containing silica and subsequently analyzed by PXRD 
to verify that the resulting material was the same as the 
starting material. 
Preparation of tibolone test tablets 
In order to evaluate the influence of polymorphism 
on tibolone tablets, two batches were prepared: test 
batch 1 (containing the polymorph I) and test batch 2 
(containing the polymorph II). First, a placebo test 
mixture was prepared using the following pharmaceutical 
grade excipients: lactose (8.68 g), starch (1.0 g), 
magnesium stearate (50 mg) and ascorbyl palmitate 
(20 mg). A 125 mg of each sieved polymorphic form 
was then individually added to two separate portions of 
4875 mg of the placebo test mixture. These substances 
were mixed in an aluminum container by vigorous 
shaking. Then, portions of one average weight (100 mg) 
were individually added to the hole punch to produce 
the tablets by direct compression, using a 6-mm punch 
diameter and a single rotary tablet compression machine 
LemaqTM model LM08B (Diadema, São Paulo, Brazil). 
The compression strength was adjusted to produce 
tablets with hardness greater than 3.0 kgf, and the same 
strength was used for the production of all tablets in both 
batches. 
Subsequently, the apparent densities (Dapp) of six 
tablets selected at random were evaluated for each batch 
using the Equation (1): 
 Dapp = m/πr2t (1)
where m is tablet weight in milligrams, r is tablet radius in 
millimeters and t is tablet thickness in millimeters.
Dissolution profiles of tibolone polymorphs from 
test tablets
The two test tablet batches, which were prepared 
according to the previous section, were subjected to the 
dissolution test conditions described for tibolone tablets 
in the British Pharmacopoeia 2011 with the exception 
of sampling time points, that were 5, 10, 15, 20, 45 and 
60 min, instead of a single sampling point at 45 min, as 
recommended. Dissolution tests were performed in an 
ElectrolabTM TDT-08 L multi bath (n=8) dissolution test 
system (Mumbai, Maharashtra, India). The dissolution 
medium was 500 mL of 0.25% w/v solution of sodium 
lauryl sulfate at 37 °C. A paddle was used as a stirring 
apparatus at 50 revolutions per minute. Five milliliters of 
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the medium were sampled at the specified sampling times, 
followed by immediate replacement of the withdrawn 
volume, and the sample was analyzed by HPLC. Six 
tablets were assayed from each batch. 
Polymorphs’ quantification by HPLC
Chromatographic equipment
Samples from solubility and dissolution studies 
were determined using a ShimadzuTM HPLC system 
series LC-10A (Kyoto, Japan), consisting of an LC AVP 
pump, a CLASS-VP 5.02 integration system, a DGU-14 
A degasser, a 7725i manual injector with a 20 μL loop, 
an SPD-10AVP integrated UV detector, a FCV-10ALVP 
valve, a CTO-10AVP column oven and an SCL-10 AVP 
controller.
Analytical conditions
Chromatographic separations were carried out using 
the following chromatographic parameters: BDS Hypersil 
C-18 column (250 x 4.0 mm, 5.0 μm, Thermo ScientificTM, 
Bellefonte, Pennsylvania, USA) at 30 °C as a stationary 
phase, acetonitrile and water (60:40 v/v) at 1.0 mL.min-1 
as the mobile phase and UV detection at 205 nm. Before 
injection, samples were filtered on PTFE hydrophilic 
filters (13 mm diameter, 0.50 µm porosity, AdvantecTM 
MSF, Dublin, California, USA). The volume of the 
sample solution injected was 20 μL. The samples were 
quantified using a calibration curve of tibolone BPCRS 
in the concentration range 1-25 µg.mL-1. 
Statistical analysis
Student’s t-test at a 0.05 significance level was used 
to compare the solubility of forms I and II in each medium 
and to compare the average density of tablet batch I to the 
average density of tablet batch II.
RESULTS AND DISCUSSION
Polymorphs’ characterization
In this work, we reproduced the recrystallization 
processes described in the literature with slight 
modifications (Sas, Van Doornum, 1991; Araujo et al., 
2010a), in order to obtain forms I and II of tibolone. To 
obtain form I, a process of recrystallization from acetone–
water was used, and to obtain form II we used toluene as a 
solvent. Several attempts to recrystallize form II in hexane 
were performed; however, contamination from form I was 
observed by PXRD analyzes in all cases. 
After recrystallization, the dried crystals were sieved 
and the size fraction between 106 μm and 150 μm was 
used in further studies. We used sieving to standardize the 
polymorphic particle size, in order to avoid influences in 
our experiments. Furthermore, this process does not utilize 
any mechanical force that could alter the crystal structure 
of the polymorphs.
PXRD is the traditional technique used to identify 
the crystalline components of APIs because every crystal 
form of a compound produces its own characteristic 
X-ray diffraction pattern. According to the USP general 
chapter on X-ray diffraction, the agreement in the 
2θ-diffraction angles between specimen and reference 
is within 0.2° for the same crystal form, while relative 
intensities between specimens and references may vary 
considerably due to preferred orientation effects (United, 
2015).
PXRD identification of crystals after recrystallization 
was carried out by comparing experimental data with 
calculated Bragg reflections from their single-crystal 
XRD structure (Declercq, Van Meerssche, Zeelen, 1984; 
Schouten, Kanters, 1991). The results are shown in Figure 
2 and Table I.
As observed in Figure 2 and Table I, the calculated 
Bragg peaks of form I match the experimental PXRD 
pattern of tibolone obtained by crystallizing in acetone–
water and there was no unidentified peak, showing that 
form II and other crystalline phases are absent. Moreover, 
the experimental PXRD pattern of tibolone crystals 
obtained from recrystallization in toluene are in good 
agreement with the calculated Bragg peaks of form II; no 
unidentified peak was observed in this sample. 
In order to confirm PXRD results, we performed 
FTIR-ATR analyses. ATR was used to eliminate the 
possibility of polymorphic transformations that can occur 
during the high pressure used in the preparation of KBr 
disks. The results are shown in Figure 3 and Table II.
Solid state spectroscopy (IR, Raman, and NMR) 
has become integral techniques for the physical 
characterization of pharmaceutical solids. IR and Raman 
spectroscopy are techniques which provide spectra based 
on the vibrational modes of the molecules. In many cases, 
IR and/or Raman spectra can identify polymorphic forms. 
Both techniques provide information on the structure and 
molecular conformation of the solid (Brittain, 2009).
As observed in Table II, recorded FTIR spectra 
of crystals were similar to those previously reported for 
polymorphs I and II using the ATR accessory (Araujo 
et al., 2010a). The differences in the spectra of forms 
I and II were attributed the conformational differences 
between the polymorphs: form II (triclinic) presents only 
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FIGURE 2 - Calculated (Declercq, Van Meerssche, Zeelen 1984; Schouten, Kanters, 1991) and experimental PXRD pattern of 
forms I and II of tibolone.
TABLE I - X-ray diffraction peaks (Positions in 2q (CuKa)) from simulated patterns of tibolone forms I and II in comparison with 
the experimental PXRD diffractograms of samples obtained from the recrystallization procedures
Form I (Calculated) 
(Declercq, Van Meerssche, 
Zeelen, 1984) 
2θ
Form I (experimental) 
2θ
Form II (Calculated) 
(Schouten, Kanters, 1991) 
2θ
Form II (experimental)  
2θ
8.57 8.57 - -
- - 8.72 8.71
12.88 12.87 - -
- - 13.49 13.49
13.53 - - -
13.70 13.72 - -
13.81 - - -
- - 13.96 13.97
13.98 13.97 - -
14.19 - - -
14.47 14.52 - -
14.99 15.02 - -
- - 15.20 15.19
15.25 15.27 - -
- - - -
- - 15.94 -
16.04 16.12 - -
- - 16.23 16.23
16.28 16.32 - -
17.20 - - -
17.29 - - -
17.30 - - -
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Form I (Calculated) 
(Declercq, Van Meerssche, 
Zeelen, 1984) 
2θ
Form I (experimental) 
2θ
Form II (Calculated) 
(Schouten, Kanters, 1991) 
2θ
Form II (experimental)  
2θ
17.43 17.42 - -
- - 17.49 -
17.52 - - -
- - 17.59 17.57
- - 17.68 -
17.83 17.87 - -
18.47 18.52 18.47 18.47
18.72 - - -
18.92 18.92 - -
19.33 19.37 - -
20.28 - - -
20.39 20.37 - -
20.47 - - -
- - 20.54 20.53
- - 20.80 20.79
- - 21.18 21.17
21.26 - - -
21.37 21.32 - -
21.54 - - -
21.62 - - -
21.70 - - -
21.94 21.92 21.94 21.93
22.12 - - -
- - 22.13 -
22.23 - - -
- - 22.37 22.35
22.96 - - -
- - 22.98 22.97
22.99 23.07 - -
23.70 - - -
- - 23.73 23.71
23.86 - - -
23.87 23.87 - -
- - 24.22 24.19
24.48 - - -
24.94 24.97 - -
25.53 - - -
25.68 25.67 - -
25.92 - - -
26.08 - - -
26.14 26.17 - -
- - 26.23 26.23
27.25 - - -
- - 26.37 -
- - 26.70 26.69
TABLE I - X-ray diffraction peaks (Positions in 2q (CuKa)) from simulated patterns of tibolone forms I and II in comparison with 
the experimental PXRD diffractograms of samples obtained from the recrystallization procedures (cont.)
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Form I (Calculated) 
(Declercq, Van Meerssche, 
Zeelen, 1984) 
2θ
Form I (experimental) 
2θ
Form II (Calculated) 
(Schouten, Kanters, 1991) 
2θ
Form II (experimental)  
2θ
- - 27.18 -
27.33 27.37 - -
27.41 - - -
27.47 - - -
27.56 - - -
27.76 - - -
- - 27.78 27.77
27.82 27.82 - -
27.91 - - -
27.99 - - -
28.02 - - -
- - 28.06 -
28.08 - - -
- - 28.14 28.11
28.16 28.12 - -
- - 28.26 -
28.33 - - -
28.42 - 28.42 -
28.50 - - -
28.59 - - -
28.61 28.67 - -
28.75 - - -
28.91 28.92 28.91 28.83
- - 28.96 28.93
29.17 - - -
29.33 29.32 - -
29.35 - - -
29.36 - - -
29.48 - - -
- - 29.49 -
- - 29.58 -
- - - -
29.51 - - -
29.74 - - -
29.90 29.87 - -
- - 29.98 -
30.06 30.02 - -
TABLE I - X-ray diffraction peaks (Positions in 2q (CuKa)) from simulated patterns of tibolone forms I and II in comparison with 
the experimental PXRD diffractograms of samples obtained from the recrystallization procedures (cont.)
one conformation, while form I (monoclinic) can exist in 
two-half-chair conformations (Figure 1). For this reason, 
C-H and O-H bands are split in the IR spectrum of form I 
(Araujo et al., 2010a).
Therefore, the results of PXRD and FTIR-ATR 
showed that both forms were successfully crystallized in 
this work with a high degree of polymorphic purity.
Solubility studies of tibolone polymorphs
Values of solubility of sieved tibolone polymorphic 
forms I and II in different aqueous solvents at 25 °C are 
shown in Figure 4.
As demonstrated in Figure 4, the solubility of form 
II is statistically higher in water, 0.01 mol.L-1 HCl and 
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FIGURE 3 - Experimental FTIR-ATR spectra of tibolone forms I and II.
TABLE II - Major absorption bands from FTIR-ATR spectra (300-3500 cm-1) of tibolone forms I and II in comparison with reported 
values (Araujo et al., 2010a)
Form I (Araujo et al., 2010a) 
(cm-1)
Form I (experimental) 
(cm-1)
Form II (Araujo et al., 2010a) 
(cm-1) 
Form II (experimental) 
(cm-1)
3251 (C–H stretching) 3252 3265 (C–H stretching) 3265
3270 (C–H stretching) 3269 3489 (OH stretching) 3489
3407 (OH stretching) 3408
3488 (OH stretching) 3489
FIGURE 4 - Solubility values of tibolone forms I and II at 25 °C. Values of form II marked with asterisks differ statistically from 
solubility values of form I at a significance level of 5%.
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pH 4.5 acetate buffer (p values of 0.04, 0.01 and 0.001 
respectively). Form II is about 1.10-, 1.26-, and 1.38-times 
more soluble in ultrapure water, 0.01 M HCl and pH 4.5 
acetate buffer, respectively, than form I. In other solvents 
tested, there was no statistical difference between the 
solubility of polymorphs. Moreover, solubility for both 
forms does not seem to be pH-dependent at 48 hours. 
In general, when polymorphs of the same molecule 
(including API) are compared, the solid-state phase with 
a lower melt point MP and thus a higher lattice free energy 
is expected to have a higher equilibrium solubility and 
faster dissolution rate (Khankari, Grant, 1995). In the 
case of tibolone polymorphs, it cannot be confirmed, since 
Boerrigter et al. (2002) demonstrated that the melt point 
of form I is 170 °C and form II exhibited transition to the 
form I at 144 °C. Nevertheless, the equilibrium solubility 
differences are predictable from the crystal packing in 
this case. Both packings present a 1D infinite network 
stabilized by intermolecular hydrogen bonds involving the 
donor/acceptor hydroxyl/carboxyl molecular extremities 
(Figure 5). However, in form I, the parallel 1D network 
is stacked in a wavy fashion, whereas parallel layers are 
observed in form II (Figure 5). It is reasonable to consider 
that the solvent-solute interaction during the dissolution 
process is more difficult in the wavy stacking than in the 
layered one, which justifies the observation that form I is 
less soluble than form II. 
The PXRD patterns (Figure 6) show that the 
solid material in equilibrium with the solutions used to 
determine solubility are constituted only by the respective 
crystal form used as starting material of Form I and II. 
That is means, no phase transition takes place during the 
solubility determination experiment.
Dissolution profiles of tibolone polymorphs from 
test tablets
Given that the bioavailability of a drug product 
depends on the dissolution of the drug from the dosage 
form as well as solubility, we have prepared test batches 
of tibolone tablets containing polymorphs I and II and 
then perform dissolution profiles on these products. For 
the preparation of tablets, the excipients were selected 
based on the qualitative composition of LivialTM 2.5 mg 
tablets (reference product on Brazil). As the quantitative 
composition is not reported by the manufacturer, we used 
commonly reported amounts of each excipient, based on 
the literature (Rowe, Sheskey, Quinn, 2009). Moreover, 
we used a direct compression process to avoid possible 
transitions in the crystal structure of tibolone polymorphs, 
which can occur due to the high humidity present in wet 
granulation. The results of dissolution profiles are shown 
in Figure 7. 
Figure 7 clearly shows the effect of polymorphism 
on the dissolution of tibolone from tablets. Firstly, we 
calculated the density of each batch to verify whether 
the dissolution rate differences are not due to different 
compaction states of the tablets. The average tablet 
relative densities for batch 1 and batch 2 were 1.180 ± 
0.017 and 1.164 ± 0.019 mg.cm-3, respectively, and were 
not statistically different (P=0.15). Diameter, thickness 
and average mass for batch 1 were 6.02 ± 0.01 mm, 2.97 
± 0.03 mm and 99.75 ± 0.76 mg, respectively (n = 6). 
Diameter, thickness and average mass for batch 2 were 
6.03 ± 0.01 mm, 3.00 ± 0.03 mm and 99.73 ± 0.61 mg, 
respectively (n = 6).
Since tibolone tablets have a small amount of 
active principle concerning excipients (2.5% of active 
principle in samples), it was not possible to identify the 
polymorphic form of tablets by XRPD or FTIR-ATR. For 
this reason, we did not compare the dissolution of LivialTM 
2.5 mg with the Form I and Form II test batches, since any 
dissolution difference between these batches and LivialTM 
could be attributed to production process variables, and 
not the polymorphic composition, therefore not adding 
information to the objectives of this work.
Because the solubility of tibolone form II is slightly 
higher in some aqueous solvents, it was expected that 
the dissolution of form II from tablets would be slightly 
higher. Nevertheless, in all sampling time points, the 
dissolution of form II was significantly lower. To exclude 
the possibility of experimental errors, we repeated the 
FIGURE 5 - Packing of forms I (a) and II (b) of tibolone 
projected onto their respective bc planes (011).
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FIGURE 7 - Dissolution profiles of tablets containing tibolone 
forms I and II. Dissolution medium: 500 mL of 0.25% w/v 
solution of sodium lauryl sulfate at 37 °C; stirring apparatus: 
paddle at 50 rpm. Six tablets were assayed for each batch. Error 
bars represent standard deviations.
FIGURE 6 - Experimental PXRD patterns of the residual solid materials in equilibrium with the solution prepared from the tibolone 
forms I and II. The calculated PXRD pattern of the tibolone forms I and II are included.
experiments and confirmed the results. These findings can 
be explained by considering that several factors can affect 
the dissolution rate of drugs from tablets besides drug-
drug intermolecular interactions, such as: particle size, 
dosage form, formulation technology, dissolution method, 
binder concentration, tablet hardness, storage conditions, 
excipients, drug-excipient interactions, etc. 
The only above-mentioned factor that was not 
strictly controlled was drug-excipient interaction, 
since each polymorph can interact with excipients in a 
particular way based on its crystal packing. Thus, we 
suppose that this factor is responsible for the lowest 
dissolution of tibolone form II. This hypothesis is 
corroborated by the work of Araujo et al. (2010b), in 
which the authors evaluated compacted binary mixtures 
of each tibolone polymorph and excipients by differential 
scanning calorimetry (DSC) and HPLC. The authors 
demonstrated that there are distinct chemical interactions 
between tibolone polymorphs and some excipients used 
in tablets. 
Solubility and dissolution studies of tibolone polymorphs
Braz. J. Pharm. Sci. 2017;53(4):e00233 Page 11 / 12
FIGURE 8 - Chromatograms of samples obtained after the 60 minute dissolution test from tablets containing form I (A) and tablets 
containing form II (B) of tibolone.
Another factor that may cause a lower concentration 
of tibolone after performing dissolution tests on tablets 
containing polymorph II, could be the greater instability 
of tibolone form II compared to form I. However, the 
analysis of chromatograms obtained after 60 minutes of 
dissolution testing showed no higher degradation of form 
II compared to form I (Figure 8). 
According to the FDA (2002), when differences in 
the aqueous solubility and dissolution rate of polymorphs 
of a drug substance are sufficiently large, the bioavailability 
is altered, and it is consequently difficult to formulate a 
bioequivalent drug product using a different polymorph. 
Therefore, only form I is acceptable for the preparation of 
tablet forms, since the substitution of form I to form II can 
significantly harm the dissolution of tibolone from tablets 
and consequently alter the bioavailability of the drug 
product, compromising the achievement of the desired 
therapeutic response. 
The possible impact of tibolone polymorphism on 
bioavailability and consequently on the clinical efficacy of 
marketed drug products is of great interest for public health 
and for academic or industrial fields. Thus, regulatory 
agencies should stimulate efforts for studies of properties 
of the different crystalline forms of drugs. 
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CONCLUSIONS
The solubility studies demonstrated that form II is 
statistically more soluble in water, 0.01 mol.L-1 HCl and 
pH 4.5 acetate buffer, with p<0.05.
Dissolution studies of test tablets containing 
tibolone forms I and II showed a significant effect of the 
polymorphism on the dissolution of tibolone from tablets, 
since the release of polymorphic form II was lower than 
the release of form I.
The results show the influence of tibolone 
polymorphs on the quality of tablets. Moreover, it is 
reported that form I is the most thermodynamically stable 
crystal form (Sas, Van Doornum, 1991). Therefore, only 
form I is acceptable for the preparation of tablets.
Based  on  these  r e su l t s ,  we  p ropose  tha t 
pharmaceutical industries should perform polymorphic 
quality control on tibolone raw materials using X-ray 
diffraction analysis and infrared spectroscopy in order 
to avoid further problems of dissolution on finished drug 
products.
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